On November 11th, the 22nd China International High-Tech Fair (hereafter referred to as "High-tech Fair") was inaugurated in Shenzhen Convention and Exhibition Center. A speech tour of academicians named “Science and China” and a signing ceremony for major projects was held by Shenzhen Institutes of Advanced Technology (SIAT) of the Chinese Academy in the afternoon. Guan Zhisheng, the Director and deputy General Manager of Hybribio Biotech, was invited to sign the contract for setting up a joint laboratory of precision medicine for SIAT and Hybribio.

As a new-generation technology of diagnosis and treatment, the precision medicine has become one of China’s significant strategies. By taking advantage of omics technologies such as genomics and proteomics, and medical cutting-edge technologies, precision medicine can perform personal diagnosis and treatment for specific diseases and patients with high-precision, leading to the improvement of benefits generated in the diagnosis, treatment and prevention of disease.

The pursuit of the country is the pursuit of Hybribio. Hybribio Biotech has been focusing on the precision diagnosis and treatment for many years by breaking through difficulties to make new achievements. With the speeding innovation in this field, the multi-faceted, trans-industrial, and trans-disciplinary cooperation is becoming a new trend.

The SIAT of the Chinese Academy of Sciences is one of the five research institutes established under the collaboration between the Chinese Academy of Sciences and the provincial and municipal governments, and it is subordinate to the Chinese Academy of Sciences as a national research institution. The establishment of the joint lab for SIAT and Hybribio is aiming at conducting forward-looking studies on innovative technology in the field of precision medicine. The contract of constructing a joint lab for SIAT of the Chinese Academy of Sciences and Hybribio, which signed by Guan Zhisheng, represents a new step for Hybribio Biotech to technological development and innovation pattern in the field of precision medicine.

The leaders from the Chinese Academy of Sciences system and relevant departments in Shenzhen, the well-known experts and scholars from universities and scientific institutions, the industrialists and media reporters all attended and witnessed the opening and signing ceremony of the joint laboratory. From now on, Hybribio Biotech will take on a new historical mission of the construction of a precision medical service system in the Guangdong-Hong Kong-Macao Greater Bay Area.

In the High-tech Fair, Hybribio’s exhibition of its latest anti-epidemic outcome and cooperation projects has attracted the attention from different parties. The scientific and technological achievements of the "13th Five-Year" and the layout of key industries of the "14th Five-Year" are the key points of this year’s Hi-Tech Fair, including biomedicine, smart healthcare, medical diagnosis, online education, remote office, and new retail industry, with a total number of over 3,300 exhibitors from domestic and overseas, and more than 10,000 items.

The continual innovation and updating of technology is the only way to provide better protection for human health. For this time, the establishment of a joint lab for the Chinese Academy of Sciences and Hybribio will integrate the national strategy and the actual needs of the biotechnology industry in the Guangdong-Hong Kong-Macao Greater Bay Area more tightly. Hybribio is hoping to integrate the Greater Bay Area's innovative resources and research outcomes under the collaboration with the Chinese Academy of Sciences, in order to promote the studies on critical technologies and following transformation process in the field of precision medicine, and make contribution to the development of China’s medical and health services.